Impressively, in a well‐designed phase III study, alectinib represented significantly superior systemic and CNS efficacy over crizotinib in treating newly‐diagnosed ALK‐positive NSCLC and ALK‐positive NSCLC with crizotinib treatment in prior.22, 23. The gene discussed is ALK; the disease is non-small cell lung carcinoma.